Impact of operator's experience on peri-procedural outcomes with Watchman FLX: Insights from the FLX-SPA registry
Ver/ Abrir
Registro completo
Mostrar el registro completo DCAutoría
Cruz-González, Ignacio; Torres Saura, Francisco; Trejo-Velasco, Blanca; Fernández Díaz, José Antonio; Fajardo Molina, Ricardo; Valle-Fernández, Raquel del; Moreno Terribas, Gerardo; Martí Sánchez, David; López-Mínguez, José Ramón; Gómez-Blázquez, Iván; Sanmartín-Peña, Juan Carlos; Botas, Javier; Martín Lorenzo, Pedro; Palazuelos, Jorge; Albarrán Rinco, Ramón; Mohandes, Mohsen; Rodríguez Entem, Felipe; Martí, Gerard; Valero, Ernesto; [et al.]Fecha
2022-02Derechos
Attribution-NonCommercial-NoDerivatives 4.0 International
© 2022 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
Publicado en
Volume 38, February 2022, 100941
Editorial
Elsevier
Enlace a la publicación
Palabras clave
Atrial fibrillation
Left atrial appendage occlusion
Devices
Outcomes
Resumen/Abstract
Background
The Watchman FLX is a device upgrade of the Watchman 2.5 that incorporates several design enhancements intended to simplify left atrial appendage occlusion (LAAO) and improve procedural outcomes. This study compares peri-procedural results of LAAO with Watchman FLX (Boston Scientific, Marlborough, Massachusetts) in centers with varying degrees of experience with the Watchman 2.5 and Watchman FLX.
Methods
Prospective, multicenter, ?real-world? registry including consecutive patients undergoing LAAO with the Watchman FLX at 26 Spanish sites (FLX-SPA registry). Implanting centers were classified according to the center?s prior experience with the Watchman 2.5. A further division of centers according to whether or not they had performed ? 10 or > 10Watchman FLX implants was prespecified at the beginning of the study. Procedural outcomes of institutions stratified according to their experience with the Watchman 2.5 and FLX devices were compared.
Results
359 patients [mean age 75.5 (SD8.1), CHA2DS2-VASc 4.4 (SD1.4), HAS-BLED 3.8(SD0.9)] were included. Global success rate was 98.6%, successful LAAO with the first selected device size was achieved in 95.5% patients and the device was implanted at first attempt in 78.6% cases. There were only 9(2.5%) major peri-procedural complications. No differences in efficacy or safety results according to the cente?s previous experience with Watchman 2.5 and procedural volume with Watchman FLX existed.
Conclusions
The Watchman FLX attains high procedural success rates with complete LAA sealing in unselected, real-world patients, along with a low incidence of peri-procedural complications, regardless of operato?s experience with its previous device iteration or the number of Watchman FLX devices implanted.
Colecciones a las que pertenece
- D22 Artículos [1134]